Last reviewed · How we verify

Wondercel Biotech (ShenZhen) — Portfolio Competitive Intelligence Brief

Wondercel Biotech (ShenZhen) pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique Hopitaux De Marseille · 1 shared drug class
  2. Centre Hospitalier Universitaire, Amiens · 1 shared drug class
  3. Hospices Civils de Lyon · 1 shared drug class
  4. I.M. Sechenov First Moscow State Medical University · 1 shared drug class
  5. Kenya Medical Research Institute · 1 shared drug class
  6. Memorial Sloan Kettering Cancer Center · 1 shared drug class
  7. National Heart, Lung, and Blood Institute (NHLBI) · 1 shared drug class
  8. Peking Union Medical College Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Wondercel Biotech (ShenZhen):

Cite this brief

Drug Landscape (2026). Wondercel Biotech (ShenZhen) — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/wondercel-biotech-shenzhen. Accessed 2026-05-16.

Related